Calpain-1 Protein

Calpain-1 Protein

Introduction

Calpain 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@vosler2022]
<table> [@cao2023]
<tr><th>Protein Name</th><td>Calpain-1 (μ-Calpain)</td></tr> [@huang2021]
<tr><th>Gene</th><td>[CAPN1](/genes/capn1)</td></tr> [@nixon2020]
<tr><th>UniProt ID</th><td>P07384</td></tr>
<tr><th>PDB IDs</th><td>1NXK, 1TL9, 3OWF</td></tr>
<tr><th>Molecular Weight</th><td>80 kDa (catalytic subunit)</td></tr>
<tr><th>Subcellular Localization</th><td>Cytoplasm, Membrane</td></tr>
<tr><th>Protein Family</th><td>Calpain family, Cysteine proteases</td></tr>
</table>
</div>

Overview

Calpain-1 (μ-calpain) is a calcium-dependent cysteine protease that catalyzes limited proteolysis of numerous substrates. It exists as a heterodimer with a regulatory 28 kDa subunit (CAPNS1). Calpain-1 is activated by micromolar calcium concentrations and plays complex roles in both normal cellular processes and pathological conditions.

Structure

Calpain-1 is composed of:

• Catalytic subunit (CAPN1, 80 kDa):
• Domain I: N-terminal propeptide (removed during activation)
• Domain II: Protease core (cysteine protease)
• Domain III: penta-EF-hand (calcium binding)
• Domain IV: Calmodulin-like (calcium binding)
• Regulatory subunit (CAPNS1, 28 kDa):
• Required for catalytic subunit stability
• Contains glycine-rich hydrophobic domains

Calpain-1 Protein

Introduction

Calpain 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@vosler2022]
<table> [@cao2023]
<tr><th>Protein Name</th><td>Calpain-1 (μ-Calpain)</td></tr> [@huang2021]
<tr><th>Gene</th><td>[CAPN1](/genes/capn1)</td></tr> [@nixon2020]
<tr><th>UniProt ID</th><td>P07384</td></tr>
<tr><th>PDB IDs</th><td>1NXK, 1TL9, 3OWF</td></tr>
<tr><th>Molecular Weight</th><td>80 kDa (catalytic subunit)</td></tr>
<tr><th>Subcellular Localization</th><td>Cytoplasm, Membrane</td></tr>
<tr><th>Protein Family</th><td>Calpain family, Cysteine proteases</td></tr>
</table>
</div>

Overview

Calpain-1 (μ-calpain) is a calcium-dependent cysteine protease that catalyzes limited proteolysis of numerous substrates. It exists as a heterodimer with a regulatory 28 kDa subunit (CAPNS1). Calpain-1 is activated by micromolar calcium concentrations and plays complex roles in both normal cellular processes and pathological conditions.

Structure

Calpain-1 is composed of:

• Catalytic subunit (CAPN1, 80 kDa):
• Domain I: N-terminal propeptide (removed during activation)
• Domain II: Protease core (cysteine protease)
• Domain III: penta-EF-hand (calcium binding)
• Domain IV: Calmodulin-like (calcium binding)
• Regulatory subunit (CAPNS1, 28 kDa):
• Required for catalytic subunit stability
• Contains glycine-rich hydrophobic domains

Activation Mechanism

Normal Function

Proteolytic Activities

• Limited proteolysis (not complete degradation)
• Cleaves cytoskeletal proteins (spectrin, [tau](/proteins/tau), MAP2)
• Processes enzymes and signaling molecules
• Activates transcription factors

Cellular Functions

• Cell motility and migration
• Cell cycle progression
• [Apoptosis](/entities/apoptosis) regulation (context-dependent)
• Synaptic plasticity
• Signal transduction

Role in Disease

Alzheimer's Disease

• [Aβ](/proteins/amyloid-beta)-induced calcium dysregulation activates calpain
• Cleaves [tau](/proteins/tau) into toxic fragments
• Activates caspase-3 (apoptosis)
• Degrades synaptic proteins
• Spectrin breakdown products (SBDPs) as biomarkers

Parkinson's Disease

• α1-Synuclein triggers calcium dysregulation
• Processes parkin (affects E3 ligase function)
• Dopaminergic neuron vulnerability
• Links to mitochondrial dysfunction

Stroke and Brain Injury

• Major calcium influx activates calpain
• Excitotoxic cell death mechanism
• Contributing to ischemic damage
• SBDPs as injury biomarkers

Other Conditions

• ALS: Motor neuron calpain activation
• HD: Mutant [Htt](/proteins/htt-protein) affects calcium homeostasis
• FTD: Tauopathies involve calpain

Therapeutic Targeting

| Strategy | Agent | Status | Notes |
|----------|-------|--------|-------|
| Cysteine protease inhibitors | E-64d | Clinical | Used in Japan |
| Selective calpain-1 inhibitors | MDL-28170 | Preclinical | Neuroprotective |
| Peptide inhibitors | Calpastatin | Research | Endogenous inhibitor |
| Brain-penetrant compounds | Various | Development | Key challenge |

Biomarkers

• Spectrin breakdown products (SBDPs)
• Calpain-cleaved [tau](/proteins/tau) fragments
• Total calpain activity

Research Directions

• Development of brain-penetrant selective inhibitors
• Biomarker validation for calpain activation
• Understanding context-dependent activation
• Combination therapies with other approaches

Animal Models

• CAPN1 knockout: viable with deficits
• Transgenic mutant calpain: neurodegeneration
• Calpain inhibitor-treated: protected in stroke

Background

The study of Calpain 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• CAPN1 Gene
• [Excitotoxicity](/mechanisms/excitotoxicity-neurodegeneration)
• [Apoptosis](/mechanisms/apoptosis)
• [Alzheimer's Disease](/diseases/alzheimers-disease)